[Federal Register: June 11, 2008 (Volume 73, Number 113)]
[Notices]
[Page 33136-33137]
[DOCID:fr11jn08-109]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-57921; File No. SR-NYSEArca-2008-46]

Self-Regulatory Organizations; NYSE Arca, Inc.; Order Granting
Accelerated Approval of Proposed Rule Change Relating to the Listing
and Trading of Shares of the NETS ISEQ 20 Index Fund (Ireland)

June 4, 2008.

I. Introduction

    On May 8, 2008, NYSE Arca, Inc. (``NYSE Arca'' or ``Exchange''),
through its wholly owned subsidiary, NYSE Arca Equities, Inc. (``NYSE
Arca Equities''), filed with the Securities and Exchange Commission
(``Commission''), pursuant to Section 19(b)(1) of the Securities
Exchange Act of 1934 (``Act'') \1\ and Rule 19b-4 thereunder,\2\ a
proposed rule change to list and trade the shares (``Shares'') of the
NETS ISEQ 20 Index Fund (Ireland) (``Fund'') issued by the NETS Trust
(``Trust''). The proposed rule change was published for comment in the
Federal Register on May 15, 2008 for a 15-day comment period.\3\ The
Commission received no comments on the proposal. This order approves
the proposed rule change on an accelerated basis.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 57805 (May 8, 2008),
73 FR 28178.
---------------------------------------------------------------------------

II. Description of the Proposal

    The Exchange proposes to list and trade the Shares pursuant to NYSE
Arca Equities Rule 5.2(j)(3), the Exchange's listing standards for
Investment Company Units (``ICUs'').\4\ The Fund is an ``index fund''
that seeks to provide investment results that correspond generally to
the price and yield performance, before fees and expenses, of publicly-
traded securities in the aggregate in the Irish market, as represented
by the ISEQ 20[supreg] (``Index''). The primary market for securities
in the Index is the Irish Stock Exchange.
---------------------------------------------------------------------------

    \4\ ICUs are securities that represent interests in a registered
investment company that holds securities comprising, or otherwise
based on or representing an interest in, an index or portfolio of
securities (or holds securities in another registered investment
company that holds securities comprising, or otherwise based on or
representing an interest in, an index or portfolio of securities).
See NYSE Arca Equities Rule 5.2(j)(3).
---------------------------------------------------------------------------

    The Exchange represents that the Index for the Fund does not meet
all of the ``generic'' listing requirements of Commentary .01(a)(B) to
NYSE Arca Equities Rule 5.2(j)(3) applicable to the listing of ICUs
based on international or global indexes.\5\ Specifically, the Index
meets all such requirements except for those set forth in Commentary
.01(a)(B)(3).\6\ The Exchange represents that: (1) Except for the
requirement under Commentary .01(a)(B)(3) to NYSE Arca Equities Rule
5.2(j)(3) relating to the five most heavily weighted component stocks,
the Shares of the Fund currently satisfy all of the generic listing
standards under NYSE Arca Equities Rule 5.2(j)(3); (2) the continued
listing standards under NYSE Arca Equities Rules 5.2(j)(3) and
5.5(g)(2) applicable to ICUs will apply to the Shares; and (3) the
Trust is required to comply with Rule 10A-3 under the Act \7\ for the
initial and continued listing of the Shares. In addition, the Exchange
represents that the Shares will comply with all other requirements
applicable to ICUs including, but not limited to, requirements relating
to the dissemination of key information such as the Index value and
Intraday Indicative Value, rules governing the trading of equity
securities, trading hours, trading halts, surveillance, and Information
Bulletin to ETP Holders, as set forth in prior Commission orders
approving the generic listing rules applicable to the listing and
trading of ICUs.\8\
---------------------------------------------------------------------------

    \5\ NYSE Arca Equities may approve a series of ICUs based on
equity security components for listing and/or trading (including
pursuant to unlisted trading privileges) pursuant to Rule 19b-4(e)
under the Act, if such series of ICUs satisfies the ``generic''
listing requirements that are set forth under Commentary .01 to NYSE
Arca Equities Rule 5.2(j)(3) and have been approved by the
Commission. See Commentary .01 to NYSE Arca Equities Rule 5.2(j)(3);
17 CFR 240.19b-4(e).
    \6\ The Exchange states that the Index satisfies the first
requirement under Commentary .01(a)(B)(3) to NYSE Arca Equities Rule
5.2(j)(3) that the most heavily weighted component stock shall not
exceed 25% of the weight of the index or portfolio. However, the
Index fails to meet the second requirement of Commentary
.01(a)(B)(3) to NYSE Arca Equities Rule 5.2(j)(3) that the five most
heavily weighted component stocks shall not exceed 60% of the weight
of the Index. The Exchange states that, as of April 18, 2008, the
five most heavily weighted component stocks represented 68.7% of the
Index weight.
    \7\ See 17 CFR 240.10A-3.
    \8\ See, e.g., Securities Exchange Act Release Nos. 55621 (April
12, 2007), 72 FR 19571 (April 18, 2007) (SR-NYSEArca-2006-86)
(approving generic listing standards for ICUs based on international
or global indexes); 44551 (July 12, 2001), 66 FR 37716 (July 19,
2001) (SR-PCX-2001-14) (approving generic listing standards for ICUs
and Portfolio Depositary Receipts); and 41983 (October 6, 1999), 64
FR 56008 (October 15, 1999) (SR-PCX-98-29) (approving rules for the
listing and trading of ICUs).
---------------------------------------------------------------------------

III. Discussion and Commission's Findings

    The Commission has carefully reviewed the proposed rule change and
finds that it is consistent with the requirements of Section 6 of the
Act \9\ and the rules and regulations thereunder applicable to a
national securities exchange.\10\ In particular, the Commission finds
that the proposal is consistent with Section 6(b)(5) of the Act,\11\
which requires, among other things, that the Exchange's rules be
designed to promote just and equitable principles of trade, to remove
impediments to and perfect the mechanism of a free and open market and
a national market system, and, in general, to protect investors and the
public interest.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78f.
    \10\ In approving this proposed rule change the Commission has
considered the proposed rule's impact on efficiency, competition,
and capital formation. See 15 U.S.C. 78c(f).
    \11\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The Commission believes that the proposed rule change should not
significantly affect the protection of investors or the public interest
or

impose any significant burden on competition. The Commission notes the
Exchange's representations that, although the Index fails to meet the
requirement relating to the five most heavily weighted component stocks
set forth in Commentary .01(a)(B)(3) to NYSE Arca Equities Rule
5.2(j)(3) by 8.7%,\12\ the Shares currently satisfy all of the other
applicable generic listing standards under NYSE Arca Equities Rule
5.2(j)(3), and will be subject to all of the continued listing
standards under NYSE Arca Equities Rules 5.2(j)(3) and 5.5(g)(2)
applicable to ICUs. Additionally, the Exchange represents that the
Shares will comply with all other requirements applicable to ICUs \13\
and that the Trust is required to comply with Rule 10A-3 under the
Act.\14\
---------------------------------------------------------------------------

    \12\ See supra note 6.
    \13\ See supra note 8 and accompanying text.
    \14\ See 17 CFR 240.10A-3.
---------------------------------------------------------------------------

    The Commission finds good cause for approving the proposed rule
change before the 30th day after the date of publication of notice of
filing thereof in the Federal Register. The Commission notes that,
because the Shares comply with all of the NYSE Arca Equities generic
listing standards for ICUs (except for missing the requirement relating
to the five highest weighted components of the Index), the listing and
trading of the Shares by NYSE Arca does not appear to present any novel
or significant regulatory issues or impose any significant burden on
competition. For these reasons, the Commission believes that
accelerated approval of the proposed rule change should provide
additional choices for investors in, and promote additional competition
in the market for, ICUs. Therefore, the Commission finds good cause,
consistent with Section 19(b)(2) of the Act, to approve the proposed
rule change on an accelerated basis.

IV. Conclusion

    It is therefore ordered, pursuant to Section 19(b)(2) of the
Act,\15\ that the proposed rule change (SR-NYSEArca-2008-46) be, and it
hereby is, approved on an accelerated basis.
---------------------------------------------------------------------------

    \15\ 15 U.S.C. 78s(b)(2).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\16\
---------------------------------------------------------------------------

    \16\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Acting Secretary.
 [FR Doc. E8-13040 Filed 6-10-08; 8:45 am]

BILLING CODE 8010-01-P


[Federal Register Volume 84, Number 90 (Thursday, May 9, 2019)]
[Notices]
[Pages 20354-20356]
[FR Doc No: 2019-09489]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2018-0604; FRL-9993-22]

TSCA Science Advisory Committee on Chemicals (SACC); Notice of
Rescheduled Public Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA is announcing the rescheduled meeting dates for the 4-day
meeting of the Toxic Substances Control Act (TSCA) Science Advisory
Committee on Chemicals (SACC) that had been previously scheduled for
January to consider and review the draft Risk Evaluation for Colour
Index (C. I.) Pigment Violet 29 (PV29) and associated documents. This
in-person meeting will also include a general TSCA orientation for the
TSCA SACC. A portion of the in-person meeting will be closed to the
public for the committee's discussion of information claimed as
confidential business information (CBI). As previously announced in
April, the public is invited to comment on the

draft risk evaluation for PV29 and related documents, including the
draft charge questions, in advance of and during this peer review
meeting. The TSCA SACC will consider these comments during their
discussions.

DATES: Meeting: The 4-day meeting will be held from 9:00 a.m. to
approximately 5:30 p.m. Eastern Time, June 18 to 21, 2019.
    Comments: Submit your written comments, following the detailed
instructions provided in Unit I.C. of this document, on or before May
17, 2019. This comment period was already announced in the Federal
Register on April 17, 2019 (84 FR 16011; FRL-9990-36 and corrected by
84 FR 16485, April 19, 2019). As described in Unit I.C., EPA will also
accept written comments at the start of meeting.
    Requests to make oral comments during the meeting will be included
on the meeting agenda if received on or before May 28, 2019. As
described in Unit I.C., such requests may also be made up to and
possibly during the meeting.
    Special accommodations: For information on access or services for
individuals with disabilities, and to request accommodation of a
disability, please contact the DFO listed under FOR FURTHER INFORMATION
CONTACT at least 10 days prior to the meeting to give EPA as much time
as possible to process your request.

ADDRESSES: In-Person Meeting: The in-person meeting will be held at the
Holiday Inn Rosslyn at Key Bridge, Rosslyn Ballroom, 1900 North Fort
Myer Drive, Arlington, VA 22209. The meeting may also be available via
webcast. Please refer to the TSCA SACC website at https://www.epa.gov/tsca-peer-review for information on how to access the webcast. Please
note that the webcast is a supplementary public process provided only
for convenience. If difficulties arise resulting in webcasting outages,
the in-person meeting will continue as planned.
    Comments. Submit your written comments, identified by docket
identification (ID) number EPA-HQ-OPPT-2018-0604, by one of the
following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be Confidential Business
Information (CBI) or other information whose disclosure is restricted
by statute.
     Mail: OPPT Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html. Additional
instructions on commenting or visiting the docket, along with more
information about dockets generally, is available at http://www.epa.gov/dockets.
    Requests to present oral comments, and requests for special
accommodations. Submit requests to present oral comments or for special
accommodations, to the DFO listed under FOR FURTHER INFORMATION
CONTACT.

FOR FURTHER INFORMATION CONTACT: Dr. Todd Peterson, DFO, Office of
Science Coordination and Policy (7201M), Environmental Protection
Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone
number:<PHONE_NUMBER>; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general. This action may
be of interest to persons who are interested in risk evaluations of
chemical substances under the Toxic Substances Control Act (TSCA).
Since other entities may also be interested in this risk evaluation,
the Agency has not attempted to describe all the specific entities that
may be affected by this action.

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit CBI information to EPA through
http://www.regulations.gov or via email. If your comments contain any
information that you consider to be CBI or otherwise protected, please
contact the DFO listed under FOR FURTHER INFORMATION CONTACT to obtain
special instructions before submitting your comments.
    2. Tips for preparing your comments. When preparing and submitting
your comments, see the commenting tips at http://www.epa.gov/dockets/comments.html.

C. How may I participate in the in-person meeting?

    You may participate in the in-person peer review meeting by
following the instructions in this unit. To ensure proper receipt by
EPA, it is imperative that you identify docket ID number EPA-HQ-OPPT-
2018-0604 in the subject line on the first page of your submissions.
    1. Written comments. Written comments on the draft risk evaluation
for PV29 and related documents should be submitted using the
instructions in ADDRESSES and Unit I.B. Submitting written comments by
the comment due date provides the TSCA SACC with the time necessary to
review the written comments before the meeting. Anyone wishing to
submit written comments at the meeting should contact the DFO listed
under FOR FURTHER INFORMATION CONTACT before the date of the in-person
meeting and must provide 30 copies to the DFO at the start of the
meeting for the DFO to distribute to the TSCA SACC and the Agency at
the meeting. The TSCA SACC will consider written comments during their
discussions.
    2. Oral comments. The Agency encourages each individual or group
wishing to make brief oral comments to the TSCA SACC during the in-
person meeting to submit their request to the DFO in order to be
included on the meeting agenda. Requests to present oral comments will
also be accepted until the date of the in-person meeting and, to the
extent that time permits, the Chair of the TSCA SACC may permit the
presentation of oral comments at the in-person meeting by interested
persons who have not previously requested time. The request to present
oral comments should identify the name of the individual making the
presentation, the organization (if any) the individual will represent,
and any requirements for audiovisual equipment.
    Oral comments before the TSCA SACC during the in-person meeting are
limited to approximately 5 minutes unless prior arrangements have been
made with the DFO. In addition, each speaker should provide 30 copies
of his or her comments and presentation to the DFO at the start of the
meeting for the DFO to distribute to the TSCA SACC and the Agency at
the meeting. The TSCA SACC will consider oral comments during their
discussions.
    3. Seating at the meeting. Seating at the meeting will be open and
on a first-come basis.

II. Background

A. Purpose of the TSCA SACC

    The Science Advisory Committee on Chemicals (SACC) was established
by EPA in 2016 under TSCA, 15 U.S.C. 2601 et seq., as amended by the
Frank R. Lautenberg Chemical Safety for the 21st Century Act, Public
Law 114-182, 140 Stat. 448 (2016), and operates in accordance with the
Federal Advisory Committee Act (FACA), 5 U.S.C. Appendix 2 (1972). The
SACC supports activities under TSCA, the Pollution

Prevention Act (PPA), 42 U.S.C. 13101 et seq., and other applicable
statutes. The SACC provides expert independent scientific advice and
recommendations to the EPA on the scientific and technical aspects of
risk assessments, methodologies, and pollution prevention measures and
approaches for chemicals regulated under TSCA.
    The SACC is comprised of experts in: Toxicology; human health and
environmental risk assessment; exposure assessment; and related
sciences (e.g., synthetic biology, pharmacology, biotechnology,
nanotechnology, biochemistry, biostatistics, PBPK modeling,
computational toxicology, epidemiology, environmental fate, and
environmental engineering and sustainability). The SACC currently
consists of 26 members. When needed, the committee will be assisted in
their reviews by ad hoc participants with specific expertise in the
topics under consideration.

B. Purpose of This Public Meeting

    EPA is announcing the rescheduled meeting dates for the TSCA SACC's
public meeting to review PV29 that was previously announced in the
Federal Register on November 30, 2018 (83 FR 61629) (FRL-9983-08). As
previously announced, the public is invited to comment on the draft
risk evaluation for PV29 and related documents, including the draft
charge questions, in advance of and during this peer review meeting.
The TSCA SACC will consider these comments during their discussions.
See 83 FR 57473, November 15, 2018 (FRL-9986-45) and 84 FR 16011, April
17, 2019 (FRL-9990-36), as corrected by 84 FR 16485, April 19, 2019.
    The focus of the TSCA SACC meeting is to peer review the Agency's
draft risk evaluation of PV29. After the peer review process, EPA will
consider reviewer comments and recommendations, and public comments to
finalize the risk evaluation. The discussion of charge questions, for
scope and clarity, originally planned for January 8, 2019, will be
folded into the rescheduled in-person meeting.
    As previously announced, approximately one hour of the TSCA SACC's
in-person meeting will be closed to the public for the TSCA SACC to
consider and discuss material that has been claimed as CBI provided to
the TSCA SACC as background for the draft risk evaluation for PV29. In
accordance with FACA section 10(d), 5 U.S.C. App. 2, and section (c)(4)
of the Government in the Sunshine Act, 5 U.S.C. 552b, this
approximately one-hour session of the TSCA SACC will be closed to the
public to avoid the potential disclosure of CBI, which is protected
from disclosure by statute. The Administrator's determination for a
closed meeting is available in the docket.

C. TSCA SACC Documents and Meeting Minutes

    EPA's draft risk evaluation for PV29, related supporting materials,
and draft charge/questions to the TSCA SACC are available on the TSCA
SACC website and in the meeting docket. In addition, the Agency will
provide additional background documents (e.g., TSCA SACC members
participating in this meeting and the meeting agenda) as the materials
become available. You may obtain electronic copies of these documents,
and certain other related documents that might be available at http://www.regulations.gov and the TSCA SACC website at https://www.epa.gov/tsca-peer-review.
    TSCA SACC will prepare the Meeting Minutes and Final Report
document summarizing its recommendations to the Agency approximately 90
days after the meeting. The meeting minutes will be posted on the TSCA
SACC website and placed in the meeting docket.

    Authority: 15 U.S.C. 2625(o) et seq.; 5 U.S.C Appendix 2 et seq.

    Dated: May 1, 2019.
Hayley Hughes,
Director, Office of Science Coordination and Policy.
[FR Doc. 2019-09489 Filed 5-8-19; 8:45 am]
 BILLING CODE 6560-50-P